More positive trials results for Kite's Tecartus CAR T-cell therapy

Adding to a string of strong clinical trials reports for its already-marketed drug, Gilead Sciences (Nasdaq: GILD) subsidiary Kite today announced the three-year follow-up results from the pivotal ZUMA-3 study of its CAR T-cell therapy Tecartus (brexucabtagene autoleucel).

Results from the analysis showed a median overall survival (OS) of 26 months and demonstrated that responses remained durable in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) with a consistent safety profile observed since the two-year analysis. These findings were presented today during a poster session at the 5th European CAR T-cell Meeting, taking place in Rotterdam, the Netherlands.

“For adult patients living with ALL, there is a need for therapeutic options that provide long-term responses,” said Dr Bijal Shah, ZUMA-3 investigator and medical oncologist, Moffitt Cancer Center, Tampa, Florida, adding: “The continued durable response and significant improvement in survival indicated by these new data can potentially establish a new standard of care for adult patients living with this aggressive form of leukemia.”